Data published showing 99% cure rate in HCV and compensated cirrhosis

17 August 2017

The Lancet Infectious Diseases has published results from a Phase III trial evaluating a combination from US drugmaker AbbVie (NYSE: ABBV) in chronic hepatitis C virus (HCV) patients with genotypes 1 to 6 and compensated cirrhosis.

Mavyret (glecaprevir and pibrentasvir) showed a 99% virologic cure rate with 12 weeks of treatment in the EXPEDITION-1 trial.

Xavier Forns, head of the hepatitis unit, Hospital Clinic de Barcelona, Spain, and lead author of The Lancet Infectious Disease paper, said: “While the HCV treatment landscape has transformed over recent years, there have been limited options for patients with specific treatment challenges, including in certain patients with compensated cirrhosis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK